Guggenheim Partners on Monday initiated coverage on Amylyx Pharmaceuticals, Inc. AMLX, noting the company is poised to open post-bariatric hypoglycemia’s (PBH) blockbuster potential.PBH is a common complication where blood sugar levels drop too low after meals in individuals who have undergone bariatric (tummy tuck) surgery.Analyst Seamus Fernandez initiated a Buy rating and a price forecast of $17, saying, “In our view, AMLX offers a compelling investment opportunity in first-in-class rare diseases medicin ...